Short answer: yes, bremelanotide is FDA-approved — but only as one specific branded product, for one specific diagnosis. Most "PT-141" sold through telehealth isn't that product.
Here's exactly what's approved, what compounded versions actually are, and why the distinction matters more than it might seem.
What's Actually FDA-Approved
The FDA approved Vyleesi (bremelanotide injection) on June 21, 2019.[1]It's approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) — low sexual desire causing real distress or interpersonal difficulty, not better explained by another medical or psychiatric condition, relationship issues, or medication effects.[2]"Acquired" means this wasn't a lifelong pattern; "generalized" means it happens regardless of situation, stimulation type, or partner.[2] Vyleesi is not approved for postmenopausal women, for men, or as a general sexual-performance enhancer — using it outside that approved population would be off-label prescribing, which is a legally distinct situation from dispensing a compounded product.[2]
Vyleesi being FDA-approved means something specific: the FDA reviewed its full New Drug Application — the clinical data, manufacturing information, formulation, dosing, and labeling — and approved that exact product for that exact indication.[1] The approved product itself is a single-dose, prefilled autoinjector containing 1.75 mg of bremelanotide in 0.3 mL, for subcutaneous injection into the abdomen or thigh.[2]
The precise takeaway:it's inaccurate to just say "bremelanotide is FDA-approved" without naming the actual product and indication. The approval applies specifically to Vyleesi 1.75 mg/0.3 mL subcutaneous injection, for acquired, generalized HSDD in premenopausal women — not to every product sold as PT-141 or bremelanotide.[1]
The Actual FDA-Approved Dosing Details
The label-recommended dose is 1.75 mg, injected at least 45 minutes before anticipated sexual activity. Neither the exact duration of benefit nor the optimal timing window is fully characterized, so the labeling doesn't promise a specific window of effect.[2] You shouldn't use more than one dose in 24 hours, and more than eight doses per month isn't recommended — more frequent use raises exposure to side effects, including temporary blood pressure elevation and skin pigmentation changes.[2]The FDA label also recommends discontinuing Vyleesi after eight weeks if there's no reported improvement in HSDD symptoms — it's not meant to be continued indefinitely without a response.[2]It's contraindicated for anyone with uncontrolled hypertension or known cardiovascular disease, since it can temporarily raise blood pressure and lower heart rate after each dose — clinicians are directed to assess cardiovascular risk before starting and periodically afterward.[2] In FDA trials, nausea was the most common reaction — 40% of Vyleesi-treated participants versus 1.3% on placebo — with flushing, injection-site reactions, headache, and vomiting also reported.[2]
What "Compounded Bremelanotide" Actually Means
Compounded bremelanotide means a pharmacy prepares a bremelanotide-containing medication based on a prescription, rather than dispensing the FDA-approved Vyleesi product itself. It can differ in dosage form, concentration, inactive ingredients, route, delivery device, or instructions — but regardless of those differences, it's not itself an FDA-approved finished drug product.[3] That's a meaningful distinction: compounded bremelanotide doesn't go through the same product-specific FDA premarket review for safety, effectiveness, manufacturing quality, or labeling that Vyleesi underwent. That doesn't mean every compounded preparation is defective — it means the two categories have materially different regulatory status and evidence available to you as a patient.[3]
Traditional compounding under Section 503A is generally performed by a licensed pharmacist or physician for a specific, identified patient, based on a valid prescription and other statutory conditions.[3]There's a regulatory wrinkle worth knowing here specifically for bremelanotide: Section 503A restricts compounding a drug that's "essentially a copy" of something already commercially available. FDA guidance states a compounder relying on 503A's exemptions generally shouldn't regularly or in large amounts compound a product that's essentially a copy of a commercially available one.[5] Since Vyleesi already exists as an FDA-approved commercial product, whether a specific compounded bremelanotide prescription is actually permissible under this rule depends on real facts — the formulation, route, and strength used, whether the FDA-approved product could meet the need, a documented clinical difference for that specific patient, state pharmacy law, and the applicable FDA requirements.[5]It's not accurate to claim every compounded bremelanotide prescription is automatically unlawful, or automatically equivalent to Vyleesi — the honest answer depends on the specifics.[3]
What Transparency Should Actually Look Like
A provider offering compounded bremelanotide should disclose the exact formulation, administration route, concentration, prescribed dose, the compounding pharmacy's name and location, and clearly state that the product is compounded rather than FDA-approved. It should also explain the specific clinical reason for using a compounded version instead of branded Vyleesi.[4]Three terms worth keeping straight, since they get blurred together constantly in marketing: "PT-141" is a name commonly used for the underlying molecule; "Vyleesi" is the specific FDA-approved brand and dosage form; a compounded product contains bremelanotide but has its own distinct, non-FDA-approved formulation and regulatory status.[2]
The Bottom Line
The practical distinction is straightforward once it's laid out clearly: Vyleesi is an FDA-approved, labeled product with a defined indication and a fixed autoinjector dose. Compounded bremelanotide can be prescribed for patient-specific reasons, but it doesn't carry that same product-level FDA approval. Neither option is automatically the "right" one — the right choice should follow a full HSDD evaluation, a real look at cardiovascular risk and contraindications, and a transparent conversation about sourcing and follow-up.[2]
Worth asking any provider directly whether they're prescribing FDA-approved Vyleesi or a compounded formulation, and if compounded, what the specific clinical reason is for that choice.
Sources
- Vyleesi (Bremelanotide) Subcutaneous Injection: FDA Approval Letter — U.S. Food and Drug Administration accessdata.fda.gov
- Vyleesi (Bremelanotide) Prescribing Information — U.S. Food and Drug Administration accessdata.fda.gov
- Regulatory Framework for Compounded Preparations — National Academies of Sciences, Engineering, and Medicine (via NCBI Bookshelf, National Institutes of Health) ncbi.nlm.nih.gov
- Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6 — American College of Obstetricians and Gynecologists acog.org
- Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act — U.S. Food and Drug Administration fda.gov
Frequently Asked Questions
Is PT-141 FDA-approved?
The molecule bremelanotide is FDA-approved only as Vyleesi, a specific 1.75 mg/0.3 mL injection, for premenopausal women with acquired, generalized HSDD. Most products marketed generically as "PT-141" are compounded, not the FDA-approved product.[1]
Is compounded bremelanotide legal?
It can be, depending on the specifics — formulation, documented clinical need, and whether it stays within Section 503A's rules against compounding something "essentially a copy" of the already-approved Vyleesi. It's not automatically unlawful, but it's also not automatically equivalent to Vyleesi.[5]
What's the difference between Vyleesi and compounded bremelanotide?
Vyleesi went through FDA's full premarket review for safety, effectiveness, and manufacturing quality. Compounded versions are prepared by a pharmacy for an individual prescription and haven't gone through that same product-specific review.[3]
What should a provider tell me if they prescribe compounded bremelanotide?
The exact formulation, route, concentration, dose, the compounding pharmacy's name and location, that it's compounded rather than FDA-approved, and the specific clinical reason for not using Vyleesi instead.[4]